Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04161248
Title Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Canadian Cancer Trials Group

B-cell lymphoma

primary mediastinal B-cell lymphoma

diffuse large B-cell lymphoma


Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Venetoclax

Age Groups: senior | adult
Covered Countries CAN

No variant requirements are available.